Ipsen: Revenue Up 22.6% in Q1, 2026 Guidance Confirmed
Ipsen reported on Thursday, April 23, a first-quarter 2026 revenue of EUR 1,074.9 million, up 22.6% at constant exchange rates. This growth, which exceeds the overall rate of 17.0% in reported data, is driven by the growth across the three therapeutic areas. The group confirms its guidance for the fiscal year 2026: growth exceeding 13.0% at constant exchange rates and an operating margin over 35.0%, reflecting management's confidence in achieving its targets.
Revenue Breakdown and Key Growth Areas
Ipsen's total revenue reached EUR 1,074.9 million in Q1 2026, up 22.6% at constant exchange rates. Oncology grew by 13.0% to EUR 707.5 million, Rare Diseases jumped 125.4% to EUR 147.1 million, and Neuroscience recorded a growth of 18.5% to EUR 220.3 million. Excluding Somatuline, the portfolio accelerated by 27.5% at constant exchange rates, demonstrating the momentum of the group's other products. This acceleration of the non-Somatuline portfolio highlights the dynamics of other products, while Somatuline, the group's flagship treatment, benefits from the challenges faced by generic lanreotide.
Anticipated Clinical Trial Outcomes and Regulatory Updates
The group anticipates several decisive study results in 2026, including three Phase III evaluations. Iqirvo and Bylvay, two products from its rare liver diseases franchise, will present their pivotal results in 2026, notably driven by the quarter's performance. Dysport will also see its Phase III data in chronic and episodic migraine published this year. As of April 22, Ipsen received conditional approval from the European Commission for Ojemda (tovorafenib) in the treatment of pediatric glioma, approved based on the FIREFLY-1 study demonstrating clinically significant tumor responses. The group also announced the voluntary withdrawal of Tazverik (tazemetostat) from all markets following new tolerance data from the ongoing SYMPHONY-1 study. Concurrently, a collaboration agreement was established with Origami Therapeutics in January to strengthen the preclinical pipeline in rare neurodegenerative diseases.
2026 Financial Outlook and Management Commentary
Ipsen confirms its guidance for the fiscal year 2026, anticipating total sales growth exceeding 13.0% at constant exchange rates, with an acceleration in the growth of the non-Somatuline portfolio and growth in Somatuline sales linked to the challenges of generic lanreotide. Based on the exchange rates in March 2026, an unfavorable effect of about 1% is expected. The operating margin of the activities is expected to exceed 35.0% of revenue. David Loew, CEO, emphasized that the group combines 'solid revenue performance coupled with continuous progression of the R&D portfolio', highlighting the strong performance of Iqirvo and Bylvay in rare liver diseases. The results for the first half of 2026 are scheduled for July 30.
